In Feb 2020, 17 SGX primary-listed stocks bought back shares for a total consideration of S$68 million. DBS, Keppel Corp and Silverlake Axis led the share buyback consideration tally, with the average buyback prices at S$24.623, S$6.720 and S$0.338 respectively. Buybacks for DBS made up S$43 million of the S$68 million total consideration.
Since 2010, DBS, OCBC & UOB have increased their combined annual income that is segmented to Greater China by 175%. Combined Greater China income grew from S$2.33 billion in 2010, to S$6.42 billion in 2019.
Manulife US REIT, Prime US REIT and Keppel Pacific Oak US REIT – are focused on the US office market. For the quarter ended 31 Dec 2019, the three trusts averaged a DPU of 1.57 US cents. The trio averaged a net property income of US$24.2 million and a gross revenue of US$38.7 million.
For the year ended 31 Dec 2019, Singapore's 3 listed banks averaged a net profit of S$5.2 billion, up 10.1% YoY. Among the 3, DBS reported the highest FY19 net profit of S$6.4 billion, reflecting a 13.6% YoY increase. Over the 2019 calendar year, the 3 banks averaged a total return of 10.0%. The 2 best performers in 2019 were DBS and UOB, with total returns of 15.5% and 12.8% respectively.
Singapore’s 43 property trusts contribute 26% of the stock market’s S$1.23 billion average daily turnover in the YTD. Trusts with the highest turnover growth, compared to 2019, include Prime US REIT, Dasin Retail Trust, Keppel Pacific Oak US REIT, CDL Hospitality Trusts & Manulife US REIT.
Singapore REITs was the top net buy sector in Jan 2020, garnering net institutional inflows of S$174.9 mln, SGX data showed. This reversed net outflows of S$102.5 mln and S$127.5 mln in Dec 2019 and Nov 2019 respectively. The top institutional net buy REITs in Jan were: CapitaLand Commercial Trust (+S$68.1 mln), Ascendas REIT (+S$64.0 mln), CapitaLand Mall Trust (+S$25.7 million) and Mapletree Industrial Trust (+S$22.3 mln).
Singapore’s 10 most traded USD denominated stocks have contributed 5% to daily stock market turnover in early 2020, while averaging 4.1% returns. Singapore’s strongest performing USD stocks in the 2020 YTD were Prime US REIT and Manulife US REIT.
Singapore’s 2 strongest sectors in the 2020 YTD have been Healthcare & REITs. The 5 trusts that have seen the highest turnover growth from 2019 were Prime US REIT, Keppel Pacific Oak US REIT, Manulife US REIT, CDL Hospitality Trusts & CapitaLand Retail China Trust.
For the quarter ended 31 December 2019, SGX's 3 largest office REITs - CapitaLand Commercial Trust, Mapletree Commercial Trust and Suntec REIT averaged a DPU of 2.362 Singapore cents, an 8.4% YoY rise in net property income to S$82.8 million, and a 9.7% YoY increase in gross revenue to S$111.9 million.
Since the end of 2019, the Health Sector has been the second strongest segment of the global stock market, closely following the performance of the Tech Sector. Singapore’s 10 most traded Health Stocks in the 2020 year to 11 Feb averaged S$26 million a day in combined turnover. The 3 most traded Singapore healthcare-related stocks in the 2020 year to 11 Feb, include Medtecs International, First REIT & UG Healthcare.
These articles are provided by SGX My Gateway.
SGX's investor education portal with market, product and investment information and events. Sign up now at sgx.com/mygateway to receive our investment updates and economic calendar.
These articles are not intended for distribution to, or for use by or to be acted on by any person or entity located in any jurisdiction where such distribution, use or action would be contrary to applicable laws or regulations or would subject Singapore Exchange Limited (“SGX”) to any registration or licensing requirement. This document is not an offer or solicitation to buy or sell, nor financial advice or recommendation for any investment product. This document is for general circulation only. It does not address the specific investment objectives, financial situation or particular needs of any person. Advice should be sought from a financial adviser regarding the suitability of any investment product before investing or adopting any investment strategies. Use of and/or reliance on this document is entirely at the reader’s own risk. Further information on this investment product may be obtained from www.sgx.com. Investment products are subject to significant investment risks, including the possible loss of the principal amount invested. Past performance of investment products is not indicative of their future performance. Examples provided are for illustrative purposes only. While each of SGX and its affiliates (collectively, the “SGX Group Companies”) have taken reasonable care to ensure the accuracy and completeness of the information provided, each of the SGX Group Companies disclaims any and all guarantees, representations and warranties, expressed or implied, in relation to this document and shall not be responsible or liable (whether under contract, tort (including negligence) or otherwise) for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind, including without limitation loss of profit, loss of reputation and loss of opportunity) suffered or incurred by any person due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information, or arising from and/or in connection with this document. The information in this document may have been obtained via third party sources and which have not been independently verified by any SGX Group Company. No SGX Group Company endorses or shall be liable for the content of information provided by third parties. The SGX Group Companies may deal in investment products in the usual course of their business, and may be on the opposite side of any trades. SGX is an exempt financial adviser under the Financial Advisers Act (Cap. 110) of Singapore. The information in this document is subject to change without notice. This document shall not be reproduced, republished, uploaded, linked, posted, transmitted, adapted, copied, translated, modified, edited or otherwise displayed or distributed in any manner without SGX’s prior written consent.